Drug Profile
ICE 1208
Alternative Names: ICE-1208; Submicron cancer therapeutic - iCeuticaLatest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator iCeutica
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (PO)
- 29 Jun 2020 Preclinical development is ongoing for Acute myeloid leukaemia (PO) (iCeutica pipeline, June 2020)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (PO)